AndroGel Safety in Older Adults Ages 50 to 64

What Is AndroGel and Why the 50-to-64 Age Window Matters

AndroGel is a hydroalcoholic testosterone gel available in 1% and 1.62% concentrations, applied once daily to the shoulders, upper arms, or abdomen. The FDA approved testosterone 1% gel in 2000 for male hypogonadism, defined as serum testosterone below 300 ng/dL on two morning measurements combined with clinical symptoms [1]. Men between 50 and 64 occupy a distinct clinical zone. They are past the steep androgen decline of their 30s and 40s, yet typically younger than the populations enrolled in older cardiovascular outcome studies. They also carry a rising burden of comorbidities: hypertension, dyslipidemia, pre-diabetes, and early prostate changes that can complicate testosterone therapy.

Hypogonadism prevalence rises sharply with age. Data from the European Male Ageing Study showed that symptomatic hypogonadism (low T plus at least three sexual symptoms) affected roughly 2.1% of men ages 40 to 49, climbing to 5.1% in men ages 50 to 59 [2]. That jump means a clinician's waiting room will see more 50-to-64-year-old men asking about testosterone than any other adult age group outside geriatrics.

The FDA label for AndroGel carries a Black Box Warning about secondary exposure in women and children, and a separate safety communication about possible increased cardiovascular risk [1]. Neither warning is age-specific, but the cardiovascular signal matters most in men who already have subclinical disease, making the 50-to-64 cohort the population where pre-treatment screening has the highest yield.

How the T-Trials Define the Evidence Base for This Age Group

The Testosterone Trials (T-Trials) are the most rigorous body of evidence for testosterone therapy in older men with low T. Published in the New England Journal of Medicine in 2016, the T-Trials enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and at least one symptom domain (sexual function, physical function, or vitality) [3]. Participants received testosterone gel titrated to a target serum level of 500 ng/dL or placebo for 12 months.

The sexual function sub-trial showed a statistically significant improvement in sexual desire and erectile function with testosterone versus placebo (P<0.001 for sexual desire) [3]. Physical function improved modestly but did not reach the pre-specified threshold for clinical significance. Vitality scores improved by about 1.3 points on the FACIT-Fatigue scale, a difference the investigators described as small.

The T-Trials enrolled men 65 and older, not 50 to 64. That gap is clinically meaningful. Men in their 50s generally have better baseline cardiovascular reserve, fewer frailty markers, and different polypharmacy profiles than 65-plus men. Extrapolating the T-Trials data to the 50-to-64 group requires judgment, not assumption. A reasonable inference is that younger men with confirmed hypogonadism and fewer comorbidities may see a more favorable benefit-risk ratio than the T-Trials population, but no large randomized trial has specifically enrolled the 50-to-64 cohort to confirm this [3].

The HealthRX clinical team uses a structured three-gate framework before initiating AndroGel in any man ages 50 to 64. Gate 1: confirm biochemical hypogonadism with two fasting morning total testosterone values below 300 ng/dL plus LH/FSH to classify primary versus secondary etiology. Gate 2: complete a 10-year ASCVD risk calculation (using the AHA/ACC Pooled Cohort Equations), baseline hematocrit, PSA, and blood pressure review. Gate 3: audit all concurrent medications for interactions (anticoagulants, insulin, corticosteroids) before writing the first prescription.

Cardiovascular Safety: What the TRAVERSE Trial Added in 2023

Cardiovascular risk is the most debated safety question in testosterone therapy for middle-aged men. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, enrolled 5,204 men ages 45 to 80 with hypogonadism (testosterone below 300 ng/dL) and either established cardiovascular disease or high cardiovascular risk [4]. Participants received testosterone 1.62% gel (AndroGel) or placebo for a median of 22 months.

The primary endpoint, a composite of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke), was non-inferior in the testosterone arm compared to placebo (hazard ratio 0.96 to 95% CI 0.78 to 1.17) [4]. That result was reassuring. However, the testosterone arm showed a higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury [4]. These secondary signals do not disqualify AndroGel use in men 50 to 64, but they do require that men with pre-existing atrial fibrillation or thromboembolic history be counseled explicitly about these risks before starting therapy.

The American Heart Association reviewed TRAVERSE data and noted that the trial was not powered to detect differences in individual MACE components, and that the atrial fibrillation finding warrants further study [5]. For the 50-to-64 man with a 10-year ASCVD risk above 10%, this information should be part of a documented shared-decision conversation, not a brief verbal mention.

Prostate Safety and PSA Monitoring

Testosterone does not cause prostate cancer. That distinction matters because clinicians and patients often conflate "raises PSA" with "causes cancer." The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend against initiating testosterone therapy in patients with prostate cancer" but does not classify AndroGel as a prostate carcinogen [6]. The concern is that testosterone can stimulate growth of pre-existing androgen-sensitive prostate cancer cells, which is why PSA screening before initiation is standard practice.

In men ages 50 to 64, baseline PSA above 4 ng/mL or a PSA velocity above 1.4 ng/mL per year over 12 months typically warrants urology referral before testosterone is started [6]. After initiation, PSA should be rechecked at 3 to 6 months. A rise of more than 1.4 ng/mL in the first 12 months of therapy is a threshold for stopping AndroGel and re-evaluating [6].

The T-Trials cardiovascular sub-study found a small increase in coronary artery non-calcified plaque volume in the testosterone group versus placebo after 12 months [7]. That finding was not accompanied by a higher rate of clinical cardiovascular events in the T-Trials themselves, but it adds nuance for men in their 50s who may have decades of testosterone exposure ahead of them if they start therapy at 52 versus 72.

Hematocrit, Polycythemia, and Thromboembolic Risk

Testosterone stimulates erythropoiesis via EPO-dependent and EPO-independent pathways. Hematocrit rise is one of the most predictable dose-related adverse effects of AndroGel. The FDA label specifies that therapy should be withheld if hematocrit exceeds 54%, and restarted at a lower dose once hematocrit falls to an acceptable level [1]. In men ages 50 to 64, baseline hematocrit often runs higher than in younger men due to subclinical sleep apnea, dehydration, or early renal changes.

A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism reviewed 35 randomized trials (N=5,mishaps) of testosterone therapy and found that testosterone increased hematocrit by a mean of 3.18 percentage points versus placebo, with polycythemia occurring in roughly 5% to 7% of treated men [8]. Sleep apnea screening before initiation is warranted in this age group because untreated apnea compounds erythropoietic drive.

Practical monitoring schedule for hematocrit during AndroGel therapy: check at baseline, at 3 months, at 6 months, and then annually if stable. If hematocrit climbs above 50% but remains below 54%, increase monitoring frequency to every 6 weeks rather than waiting for the annual check [6].

Drug Interactions Common in the 50-to-64 Age Group

Men in their 50s carry an average of 2.7 chronic medications, and several common drug classes interact directly with testosterone [9]. The three interactions that require explicit counseling before AndroGel is prescribed are listed below.

Oral anticoagulants (warfarin): Testosterone may potentiate warfarin's anticoagulant effect by reducing metabolism of the S-enantiomer via CYP2C9 inhibition. INR should be checked within 2 weeks of starting, stopping, or dose-adjusting AndroGel in any man on warfarin [1].

Insulin and oral antidiabetics: Testosterone improves insulin sensitivity. Men on insulin or sulfonylureas may need dose reductions within the first 8 to 12 weeks of AndroGel therapy to avoid hypoglycemia. The FDA label includes this interaction explicitly [1].

Corticosteroids: Concurrent use can worsen fluid retention and edema. Men with congestive heart failure or borderline renal function who require chronic corticosteroids require closer monitoring if AndroGel is added [1].

A 2019 analysis in JAMA Internal Medicine found that polypharmacy (five or more concurrent medications) was associated with a 35% higher rate of adverse drug events in men receiving testosterone therapy compared to those on three or fewer medications [10]. That figure underscores why medication reconciliation is a clinical requirement, not an optional checklist item.

Skin Transfer Risk and Household Safety

The Black Box Warning on AndroGel specifically addresses unintended transfer of testosterone to women and children through skin contact [1]. Women exposed to testosterone gel can develop virilization (clitoral enlargement, acne, voice changes), and children can develop premature pubic hair and accelerated bone age. The FDA documented 20 pediatric exposure cases between 2004 and 2009, leading to the 2009 strengthened labeling requirement [11].

For men ages 50 to 64 who live with partners or children, two mitigation strategies are effective. First, apply AndroGel only to the shoulders and upper arms (not the abdomen if physical contact is likely), cover the application site with clothing, and wash hands immediately. Second, avoid skin-to-skin contact with the application site for at least 2 hours after application. Showering before contact provides additional protection [1].

Male partners in same-sex relationships are at lower clinical risk of virilization from secondary exposure, but testosterone transfer remains measurable and should still be minimized.

Initiating AndroGel in Men Ages 50 to 64: Dose and Titration

The FDA-approved starting dose for AndroGel 1.62% is 40.5 mg (two pump actuations) applied once daily to the shoulders or upper arms [1]. For AndroGel 1%, the starting dose is 50 mg (four pump actuations or one 50 mg packet) applied to the shoulders, upper arms, or abdomen [1].

Serum testosterone should be measured 14 days after initiation to confirm levels are within the normal range (300 to 1 to 000 ng/dL). Blood should be drawn in the morning, 2 to 8 hours after application, to capture peak absorption [6]. If total testosterone remains below 300 ng/dL, the dose of AndroGel 1.62% may be increased to 60.75 mg, then 81 mg if needed, up to a maximum of 81 mg daily [1].

The Endocrine Society guideline recommends targeting mid-normal range testosterone (400 to 700 ng/dL) in older men to minimize erythrocytosis and fluid retention risk while achieving symptomatic benefit [6]. Aiming for the top of the normal range (800 to 1 to 000 ng/dL) in a 55-year-old man with baseline hematocrit of 48% and atrial fibrillation history is not the same clinical decision as it would be for a 52-year-old with no cardiovascular history and hematocrit of 42%.

Monitoring Schedule After Starting AndroGel

A structured monitoring plan reduces the probability of missing dose-related adverse effects. The Endocrine Society 2018 guideline recommends the following schedule [6]:

At 3 to 6 months post-initiation: serum total testosterone (morning, 2 to 8 hours post-application), hematocrit, PSA, blood pressure, and a symptom review using a validated tool such as the ADAM questionnaire or the International Index of Erectile Function.

At 12 months: repeat all of the above plus a fasting lipid panel and glucose. Testosterone has variable effects on lipid profiles. The T-Trials found a small reduction in HDL cholesterol (mean 1.5 mg/dL) in the testosterone group at 12 months [3], and men 50 to 64 who are already borderline for statin initiation may cross a treatment threshold after a year on AndroGel.

Annually thereafter: all parameters above plus bone density (DXA) if the patient had baseline osteopenia, given testosterone's protective effect on bone mineral density [12]. A 2021 JAMA study found that men with hypogonadism who received testosterone for 24 months showed a 7.5% increase in lumbar spine bone density versus 1.0% for placebo (P<0.001) [12].

Symptoms That Justify Starting vs. Symptoms That Do Not

Not every 55-year-old man with fatigue and reduced libido has hypogonadism, and not every man with low testosterone needs AndroGel. The Endocrine Society guideline is explicit: testosterone therapy should be offered only to men with both biochemical hypogonadism AND symptoms attributable to low testosterone [6]. Symptoms that correlate most specifically with low testosterone include decreased spontaneous erections, loss of libido, reduced testicular volume, and hot flashes. Fatigue, poor concentration, and low mood overlap substantially with depression, thyroid disease, sleep apnea, and cardiovascular disease, all of which must be excluded before attributing them to low T [6].

The American Urological Association's 2018 testosterone deficiency guideline adds that a single low testosterone measurement is insufficient for diagnosis. Two separate morning measurements below 300 ng/dL, ideally from the same lab with the same assay, are required before prescribing [13]. This two-sample rule matters particularly in the 50-to-64 group because stress, acute illness, obesity, and opioid use can all suppress testosterone transiently without reflecting true primary or secondary hypogonadism.

Bone Health Benefits in the 50-to-64 Age Range

Bone loss in men begins in the 50s and accelerates with hypogonadism. Testosterone stimulates osteoblast activity directly and indirectly through conversion to estradiol (via aromatase), which is the dominant hormone protecting male bone density [14]. Men with total testosterone below 200 ng/dL have fracture rates roughly double those of eugonadal men of the same age [14].

AndroGel therapy in hypogonadal men ages 50 to 64 may slow bone loss, but the evidence for fracture reduction specifically is limited. The T-Trials bone sub-trial found increased volumetric bone mineral density at the lumbar spine and femoral neck in testosterone-treated men versus placebo at 12 months [7]. Translating density gains into fracture prevention requires longer follow-up than any completed testosterone trial has provided.

Men in this age group who also meet criteria for osteoporosis treatment (T-score below minus 2.5 by DXA) should receive standard pharmacotherapy such as alendronate 70 mg weekly or zoledronic acid 5 mg IV annually, regardless of testosterone status [15]. AndroGel is not a substitute for bisphosphonate therapy in confirmed osteoporosis.

Sexual Function Outcomes in Men Ages 50 to 64

Sexual dysfunction is the most common symptom driving testosterone evaluation in this age group. The T-Trials sexual function sub-trial showed significant improvement in sexual desire, erectile function, and sexual activity in men receiving testosterone versus placebo at 12 months [3]. Mean scores on the PDAS (Psychosexual Daily Assessment) improved by 2.64 points in the testosterone group versus 0.54 points for placebo (P<0.001) [3].

For men with co-existing erectile dysfunction and hypogonadism, the combination of AndroGel plus a PDE5 inhibitor (sildenafil or tadalafil) may produce better erectile outcomes than either agent alone. A 2014 Cochrane review found that combination therapy improved IIEF-EF domain scores by 4.2 points more than PDE5 inhibitor monotherapy in hypogonadal men [16]. PDE5 inhibitors do not raise testosterone; they address the vascular and smooth-muscle components of erectile function that testosterone alone does not fully correct.

When to Stop or Not Start AndroGel in Men Ages 50 to 64

Absolute contraindications per FDA labeling and Endocrine Society guidelines include breast cancer, known or suspected prostate cancer, hematocrit above 54%, untreated severe obstructive sleep apnea, and uncontrolled heart failure [1, 6]. Men with PSA above 4 ng/mL require urology clearance before initiation [6].

Relative contraindications that require extra caution in men ages 50 to 64 include: established atrial fibrillation (given the TRAVERSE signal) [4], history of deep vein thrombosis or pulmonary embolism, baseline hematocrit above 50%, and active use of warfarin without the ability to monitor INR frequently [1]. Men with a recent cardiovascular event (MI or stroke within 6 months) were excluded from TRAVERSE; clinical guidelines do not support starting AndroGel within 6 months of an acute cardiovascular event [4, 6].